Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Capecitabine 35Oxaliplatin 32Fluorouracil 29Leucovorin 26Irinotecan 22Bevacizumab 19Cetuximab 17Radiotherapy 16Radiation 11Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Celecoxib 5Neoadjuvant Therapy 4Immunohistochemistry 4Biopsy 4Amplified Fragment Length Polymorphism Analysis 4cediranib 3Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Folfox protocol 3Drug Therapy 3Cisplatin 3sargramostim 2regorafenib 2pembrolizumab 2fludarabine phosphate 2aldesleukin 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rectal Neoplasms × veliparib × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡